Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.71 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995667 | 1.00 | CTSS (0.71) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL1103803 | 1.00 | CTSS (0.71) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL995669 | 1.00 | CTSS (0.71) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL10193136 | 0.94 | CTSS (0.62) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL1104461 | 0.93 | CTSS (0.61) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12362375 | 0.93 | CTSS (0.61) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL998316 | 0.93 | CTSS (0.61) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL14973626 | 0.92 | CTSS (0.80) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL14973624 | 0.92 | CTSS (0.80) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL1103513 | 0.92 | CTSS (0.58) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| EP-2937339-A1 | Macrocylic inhibitors of hepatitis c virus | Janssen Sciences Ireland UC (IE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2322516-B1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R & D IRELAND (IE) | 2015-08-06 | — | — | US | disclosed |
| US-9040562-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2015-05-26 | — | — | US | disclosed |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R&D IRELAND (IE) | 2014-09-11 | — | — | US | disclosed |
| US-8741926-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-03 | — | — | US | disclosed |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-08-22 | — | — | US | disclosed |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8349869-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2013-01-08 | — | — | US | disclosed |
| US-20120171157-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2012-07-05 | — | — | US | disclosed |
| US-8153800-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-10 | — | — | US | disclosed |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-12-01 | — | — | US | disclosed |
| EP-2322516-A1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | Tibotec Pharmaceuticals Ltd. (IE) | 2011-05-18 | — | — | EP | disclosed |
| EP-1912999-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-05 | — | — | EP | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, HCCS, CYP3A7 | CTSS 1858/4885ADRB3 2867/4885ADRA2B 3619/4885 |
| US-20120171157-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.